Background and purpose: Treatments for progressive-onset multiple sclerosis (MS) are lacking. To improve the disease management for progressive-onset MS, the differences between relapse-onset MS and progressive-onset MS in patient-reported disability, progression and symptoms were examined. Methods: A total of 1985 participants of the Australian Multiple Sclerosis Longitudinal Study were included. Associations between onset type and outcomes were assessed with negative binomial regression. Results: The severity of 17 of the 19 outcomes was significantly higher for progressive-onset MS patients than relapse-onset MS patients, including perspectives from disability, progression over the last year, fatigue, sensory, walking difficulties, pain, balance, spasticity, sexual dysfunction, bladder, bowel, anxiety, depression and the European quality of life (EQ-5D) (P < 0.05; adjusted mean ratio ranged from 1.11 to 1.52). The differences between the two onset types were most pronounced early in the disease process and reduced with increasing MS duration, and the interaction was significant for disability, progression over the last year, walking difficulties, bladder problems, bowel problems and spasticity. Conclusion: Participants with progressive-onset MS were significantly worse off on nearly all patient-reported outcomes than relapse-onset MS participants, and the differences were most pronounced early in the disease course, highlighting the importance of early intervention for those with progressive-onset MS.
Introduction
Multiple sclerosis (MS) can be clinically divided into relapse-onset MS, which starts with acute neurological impairment followed by complete or partial remission, and progressive-onset MS, which starts with a progressive phase without relapses or remissions [1] . There are certain clinical differences between relapseonset and progressive-onset. For example, the female:-male ratio is much closer to 1:1 in progressive-onset MS [2] , the latitudinal gradient is absent [3, 4] and the mean age at onset is around 9-10 years later [5] . Also, the pathophysiology may be somewhat different, with more diffuse axonal degeneration in progressive-onset MS rather than the inflammatory demyelinating lesions seen in relapse-onset MS, although this remains controversial [6] .
In recent years, dramatic progress has been made in understanding relapse-onset MS in terms of risk factors and therapies [7, 8] , but similar knowledge of progressive-onset MS is quite sparse. Only one treatment, ocrelizumab, has recently been shown as being effective in reducing disability progression and magnetic resonance imaging (MRI) changes in patients with primary progressive MS (PPMS) [9] . The limitations in understanding progressive-onset MS are partly due to the low numbers of people with this phenotype (~12% of MS) [10] , which has prevented separate sub-type analyses in most observational and clinical trial studies due to insufficient power. In addition, the typical study duration of 2-3 years is probably insufficient to reliably measure disability progression. Although the Expanded Disability Status Scale (EDSS) is often used as a primary outcome measure in clinical trials, it is strongly determined by ambulation and lacks sensitivity and specificity [11] . Whilst MRI parameters and biomarkers are of great interest, their correlation with clinical disability or symptoms is moderate [11] .
Defining differences between the two onset types may be the first step in clarifying the underlying mechanisms of progressive-onset MS compared to relapse-onset MS. As reducing symptom severity and enhancing quality of life are the ultimate goals of progressive-onset MS management, patient-reported outcome measures have become an increasingly important field of research [12] . There are several large studies [13, 14] that have looked at those measures, but they examined them by disease type [1] rather than onset type. Differences by disease type may reflect the effects of disease duration, age and age-associated comorbidities instead of true differences between onset types. Therefore, it is our aim to examine differences between progressive-onset MS and relapse-onset MS in relation to disability, disability progression, symptom severity and quality of life based on patient-reported outcomes.
Methods

Participants
The study sample was recruited from the Australian Multiple Sclerosis Longitudinal Study (AMSLS) database. The AMSLS participants have been shown to be representative of the Australian MS population and an estimated 96% of participants are diagnosed with definite MS according to the McDonald criteria [15] . Recruitment to the AMSLS is ongoing to counter the attrition rate and is being undertaken with the assistance of all Australian State and Territory MS Societies. Written informed consent forms for the survey were provided by each participant. Ethical approval for the study was originally granted by the Australian Capital Territory Human Research Ethics Committee and in 2014 by the Tasmanian Health and Medical Human Research Ethics Committee after the study centre was relocated to Tasmania.
Survey and respondents
All 3208 active AMSLS participants were invited to complete the 2015 Medication and Disease Course Survey (2179 invitations for the online survey, 1029 for the paper survey determined by participant preference). Of those, 1985 (62%) completed the survey (1459 online, 526 paper).
Outcome measures
In total, 19 patient-reported outcomes were recorded in the survey. The Patient-Determined Steps Scale (PDDS) measures mobility across nine levels and correlates strongly with the EDSS (r = 0.78) [16] . The Fatigue Severity Scale is a commonly used patientreported measurement to assess fatigue in the preceding week [mean of nine items (1-7 scale)] [17] . Anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS) [18] [total score of 14 items (1-4 scale)]. The European quality of life (EQ-5D) assessed health-related quality of life [five items, 1-5 scale, converted to a utility score from 0 (death) to 1 (perfect health)] [19] .
The remaining 14 outcomes were assessed with one single numeric rating item from 0 (no problems/progression) to 10 (worst possible symptoms/progression). Participants rated the speed of progression by which their MS progressed over the previous 12 months. The severity of 13 symptoms (walking difficulties, difficulty with balance, fatigue, bladder problems, sexual dysfunction, spasticity, sensory symptoms, bowel problems, pain, feeling of depression, cognitive symptoms, feeling of anxiety and vision problems) was rated by comparing with before they developed MS.
Other measures
Multiple sclerosis onset type was derived from their reported MS type: PPMS, relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), progressive relapsing MS (PRMS) and unsure. Progressive-onset type included PPMS and PRMS, whilst relapse-onset type included RRMS and SPMS. MS onset type was also assessed by a physician between 2002 and 2006 on a subset of participants (n = 1089), and a further subset (n = 370) had two physician reports. The measures of agreement between patient-reported and physicianreported onset type (per cent agreement 89.7%; kappa 0.53) were similar to the measures of agreement between physicians where two physician reports were completed (per cent agreement 90.0%; kappa 0.51). Other demographic characteristics included were sex, date of birth, year of diagnosis and highest education level.
Data analysis
Association was evaluated using negative binomial regression. To confirm the robustness of our conclusions to the choice of statistical model, associations using alternative regression techniques were also estimated: linear regression with transformation of the outcome scores (severity of fatigue, sensory symptoms, Fatigue Severity Scale, HADS Anxiety and HADS Depression), Cragg hurdle regression (zero-inflated pain and sexual dysfunction scores) or Tobit regression (right-censored EQ-5D scores). The findings were not materially altered by the use of these alternative statistical models.
For each outcome, potential confounders were identified using causal diagrams, and an examination of whether the coefficient of the binary covariate for MS onset type was altered by more than 10% when a covariate for the confounder was added to the model was made. Statistical interaction was assessed by a Wald test of the coefficient of a covariate formed as the product of the binary covariate for MS onset type and the covariate for the putative modifier. STATA (version 14; StataCorp LP, College Station, TX, USA) was used for all data analysis.
Results
Of all participants, 11.6% had progressive-onset MS (Table 1) . Amongst those who were unsure and had a physician MS type diagnosis (n = 145), 11.0% had progressive-onset MS. The mean age of progressiveonset participants was 8 years greater than relapseonset participants. Comparing those who responded to this survey with those who did not, similar distributions by sex (P = 0.47) and disease duration (P = 0.08) were found. However, responders were older at participation (+2.2 years, P < 0.001) and diagnosis (+1.6 years, P < 0.001) and had a higher education level [+0.1 unit (on a scale from 1-5),
For all outcomes, mean values were worse for progressive-onset MS participants (Table 2) . Amongst progressive-onset cases, the symptom with the highest mean value was walking difficulties (6.82), whilst amongst relapse-onset MS, the highest mean value was seen for fatigue (4.94). For both onset types, vision problems had the lowest mean value. In univariable analyses, the mean severity was significantly higher for those with progressive-onset MS compared to those with relapse-onset MS for most outcomes. The strongest association was for PDDS, where the mean level of walking difficulties for progressive-onset MS patients was 1.86 times greater than that of relapse-onset MS patients. After adjusting for confounders, magnitudes of the effect were reduced somewhat for most outcomes, but remained significant. The magnitudes of the effect for anxiety and depression increased because of negative confounders (e.g. HADS Depression, age; HADS Anxiety, sex, age, age at diagnosis and MS duration), which made the association significant for HADS Anxiety. No differences were seen for cognitive symptoms or vision problems.
Whether there were interactions by sex, age, age at diagnosis or MS duration was next examined. A consistent pattern of interaction with MS duration was identified, where the difference in outcomes between progressive-onset and relapse-onset was particularly pronounced for those who were still early in the disease process and the difference was attenuated for those who had had MS for longer at the survey time. This pattern was statistically significant for walking difficulties, bladder problems, spasticity, bowel problems, progression over the last year and disability level ( Fig. 1 ). For those with progressive-onset MS, the outcome severities were already high early in the disease course with relatively little increase over time after that. For those with relapse-onset MS, the severity was low early in the disease course and increased more strongly over time.
There was some concern that people with progressive-onset MS had a delayed MS diagnosis which could partly explain a higher outcome severity early in the disease process. On a sample of 1628 AMSLS patients, data on both the year of first symptom and the year of diagnosis were available. The gap between the year of first symptom and the year of diagnosis was similar for both onset types (5.4 AE 7.0 years for progressive onset, and 4.6 AE 6.8 years for relapse onset; P = 0.14 for test of difference).
As those with PRMS may be different from those with PPMS, the analysis was repeated excluding PRMS participants (Table S1 ). The symptom severity of those with PPMS was generally similar to those with PRMS, although the mean severity was somewhat lower for PPMS in some symptoms, resulting in slightly lower effect sizes compared with relapse-onset participants (e.g. sensory symptoms, pain, HADS Anxiety). This supported the inclusion of PRMS cases with PPMS cases in this analysis.
Discussion
In this large national sample of Australians with MS, it was found that people with progressive-onset MS were significantly worse off for nearly all patientreported outcomes after accounting for confounding factors like age and disease duration, and the differences were most pronounced early in the disease course, highlighting the importance of early intervention for those with progressive-onset MS. This is the first study focusing on the comparison of symptoms and disability between progressive-onset MS and relapse-onset MS from the patients' perspective. Studies showed that people with progressiveonset MS were worse off in terms of disability as measured by EDSS, Multiple Sclerosis Severity Score and PDDS, but they often compared MS types, rather than onset types. Age and disease duration are important confounders in these associations and need to be carefully taken into account in such cross-sectional comparisons [20] . It was found that, even after taking confounding factors into account, the severity of outcomes in those with progressive-onset MS was significantly worse than for those with relapse-onset MS for all outcomes except cognitive function and vision problems. For example, compared to those with h 29 values of EQ-5D were negative, which means these patients were worse than dead. To do the analysis, these values were replaced with zero. Bold values indicate significance (P < 0.05).
relapse-onset MS the mean severity for progressiveonset MS was 1.52 times higher for walking difficulties. Importantly, it was also found that the differences in outcome were most pronounced early in the disease course, this interaction being significant for six of the outcomes. This is consistent with some indirect evidence in the literature regarding disability. For example, PDDS-measured disability in cases with PPMS was significantly higher than for those with SPMS, and the difference decreased with increasing disease duration [20] . The rate of disability accumulation was similar between relapse-onset MS and progressiveonset MS when using higher EDSS milestones (such as from EDSS 6-8) [21, 22] . This has raised the argument that progressive-onset MS and SPMS are the same or at least have the same mechanisms of disease progression [23] .
Our findings show that the work should not only focus on disease-modifying treatments but also on Figure 1 Associations between MS duration and severity of outcomes for those with progressive-onset MS and relapse-onset MS, showing that the difference between the two onset types was particularly pronounced early in the disease process and diminished over time (P values for interaction provided between parentheses). [Colour figure can be viewed at wileyonlinelibrary.com] symptomatic management. The assessment and management of specific symptoms in patients with MS are complex and multifaceted, with different symptoms influencing each other. For example, treatment of pain in MS often utilizes central nervous system active drugs such as pregabalin or carbamazepine [24, 25] , both of which can worsen cognition. Similarly, the treatment of bladder hyperactivity with anticholinergics can worsen constipation and cognition [26] . Our work also clearly demonstrates the need for early interventions. Clinical trials in progressive MS patients should have a specific focus on early MS, as gain could be made by earlier intervention to reduce the total burden of progressive MS. A recently published successful trial in PPMS included patients where substantial disability had already accrued (EDSS 3.5-6.5) [9] . Indeed, the mean disease duration since symptom onset was 6 years in this trial [9] , suggesting that there is the potential to treat earlier in the disease course. The focus on early interventions aligns with the use of immunotherapy treatments in those with relapsing-onset MS, where it has been shown that early treatment seems to substantially benefit outcomes compared to delayed treatment.
A key strength of this study is that the AMSLS is a large representative dataset with a sufficient number of people with progressive-onset MS to obtain reliable estimates. One limitation was that the response rate was moderate, which may result in selection bias. Those who responded had a slightly higher age, age at diagnosis and higher education level, but the differences were not large relative to the total variation in the sample. Our cohort was somewhat more female dominated, possibly reflecting a lower male engagement in studies such as these. However, sex was not a major driver of most outcomes, and was adjusted for if it were a confounder (e.g. sexual dysfunction, HADS Anxiety) and therefore did not bias our reported outcomes.
The validity of the assessment of onset type was high (89.7% agreement). However, if it were possible to remove this measurement error, associations may have been even stronger. Despite 11.7% of participants selecting 'unsure' for their disease type, which reduced our sample size, there is some confidence about the onset phenotype in the remaining sample, therefore reducing measurement error. In addition, amongst those unsure cases (n = 145) who had physician reports done, 11.0% had progressive-onset MS, suggesting that this group had a similar distribution in onset type compared to the rest of our dataset (11.6% progressive-onset MS). There was some concern that patients with progressive-onset MS had a delayed diagnosis, possibly contributing to a worse outcome severity in early MS; however, the gap between the year of first symptom and the year of first diagnosis was similar in both onset types.
In conclusion, our study highlights the need to identify disease-modifying and symptomatic treatments and to test treatments early in the disease process.
